Clinical Efficacy of OM-85 BV in COPD and Chronic Bronchitis: A Systematic Review

OM-85 BV is an immunomodulatory agent used for prevention of exacerbations in persons with chronic lung disease. We conducted a systematic review of OM-85 BV to evaluate its efficacy and safety. A systematic search for relevant articles was performed. Studies were included if they involved persons with chronic obstructive pulmonary disease or chronic bronchitis and were randomized to OM-85 BV or placebo. Investigators extracted data on study design, participant characteristics, and clinical outcomes. Thirteen trials involving 2066 individuals met inclusion criteria. Three trials enrolled an older, more homogenous population with chronic obstructive pulmonary disease. Utilizing quantitative pooled analysis in these studies, with one or more acute exacerbations as the endpoint, we found a non-statistically significant trend in favor of OM-85 BV [relative risk 0.83, 95% confidence interval 0.65–1.05]. Ten trials enrolled a heterogeneous population with chronic bronchitis. In these trials, exacerbation rates were less with OM-85 BV in 4 of 9 trials reporting this outcome. Varied results in the outcomes of hospitalization, symptom scores, and antibiotic or steroid use were found across studies. Withdrawals and adverse events were similar between OM-85 BV and placebo. While OM-85 BV is used to prevent exacerbations in persons with chronic lung disease, consistent evidence across multiple important outcomes does not exist to clearly demonstrate clinical benefit. Further randomized controlled trials enrolling large numbers of persons with well-defined COPD are necessary to confirm the effectiveness of this agent.

[1]  James D Crapo,et al.  Clinical research in chronic obstructive pulmonary disease: needs and opportunities. , 2003, American journal of respiratory and critical care medicine.

[2]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[3]  U. Schaad,et al.  Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. , 2002, Chest.

[4]  J. Vestbo,et al.  Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study , 2002, Thorax.

[5]  Abdullah Alsaeedi,et al.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. , 2002, The American journal of medicine.

[6]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[7]  P. Holt,et al.  Selective Enhancement of Systemic Th1 Immunity in Immunologically Immature Rats with an Orally Administered Bacterial Extract , 2001, Infection and Immunity.

[8]  A. Berber,et al.  Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. , 2001, Chest.

[9]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[10]  G. Bartsch,et al.  A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells. , 2001, Immunology letters.

[11]  M. Roth,et al.  Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines , 2000, Thorax.

[12]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[13]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[14]  K. Nichol,et al.  Relation between Influenza Vaccination and Outpatient Visits, Hospitalization, and Mortality in Elderly Persons with Chronic Lung Disease , 1999, Annals of Internal Medicine.

[15]  M. Goldman,et al.  Bacterial extract OM85-BV induces interleukin-12-dependent IFN-gamma production by human CD4+ T cells. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  J. Collet,et al.  Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. , 1997, American journal of respiratory and critical care medicine.

[17]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[18]  D K Menon,et al.  Survey of intensive care of severely head injured patients in the United Kingdom , 1996, BMJ.

[19]  C. Donner,et al.  Lung immune defences after stimulation of gut-associated lymphoid tissue with' OM-85 BV: a 'double-blind study in patients with chronic bronchitis , 1996 .

[20]  W. Knaus,et al.  Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. , 1996, JAMA.

[21]  M. Clarke,et al.  Identifying relevant studies for systematic reviews , 1995, BMJ.

[22]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[23]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[24]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[25]  K. Dickersin,et al.  Systematic Reviews: Identifying relevant studies for systematic reviews , 1994 .

[26]  B. Delclaux,et al.  Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. , 1994, The European respiratory journal.

[27]  M. Kramer,et al.  Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicrèche Research Group. , 1993, The Pediatric infectious disease journal.

[28]  M. Khedr.  Clinical and immunological efficacy of broncho-vaxom® in chronic bronchitis: a double-blind study , 1993 .

[29]  S. Ashmawi,et al.  Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis , 1993 .

[30]  D. Varonos,et al.  CLINICAL EFFECTIVENESS OF BRONCHO-VAXOM (BV) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE , 1993 .

[31]  M. Goldman,et al.  Upregulation of adhesion molecules induced by broncho-vaxom on phagocytic cells. , 1992, International journal of immunopharmacology.

[32]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[33]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[34]  W. Schlenter,et al.  Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis--a multi-centric, placebo-controlled, double-blind study. , 1989, International journal of clinical pharmacology, therapy, and toxicology.

[35]  B. Čvoriščec,et al.  Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. , 1989, Respiration; international review of thoracic diseases.

[36]  O. Djuric,et al.  Effect of broncho-vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study , 1989 .

[37]  J. Bauer,et al.  Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. , 1989, International journal of immunopharmacology.

[38]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[39]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[40]  R. Keller,et al.  [Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis]. , 1984, Praxis und Klinik der Pneumologie.

[41]  T. Fux,et al.  [Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial]. , 1981, Revue medicale de la Suisse romande.